Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

Recruiting Phase 4 Interventional Study
Major Depressive Disorder Chronic Major Depression, Recurrent
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
50 (estimated)
Sponsor
University of Texas at Austin · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fM…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * English as primary language, and comprehension suitable to understand experimenter instructions * Meet criteria for a current major depressive episode diagnosed through the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders 5th edition …
Contacts

Greg Fonzo, Ph.D.

512-495-5856

fonzolab@austin.utexas.edu

CONTACT

Lauren Enten, B.S.A

lauren.enten@austin.utexas.edu

CONTACT